Management ChangeAug 3, 2026, 07:31 AM
Medicus Pharma Appoints Faisal Mehmud as CEO of UK Subsidiary Antev
AI Summary
Medicus Pharma Ltd. announced the appointment of Faisal Mehmud, MD, MRCP, as Chief Executive Officer of its UK subsidiary, Antev Limited, effective August 30, 2026. Dr. Mehmud will also continue in his roles as Chief Medical Officer of Medicus and Co-Chairman of Antev. This strategic appointment aims to strengthen the company's leadership as it advances the global development of Teverelix® across multiple indications. Dr. Mehmud, with over 20 years of global pharmaceutical experience, succeeds Amit Kohli, who served as interim CEO of Antev for one year following its acquisition.
Key Highlights
- Faisal Mehmud appointed Chief Executive Officer of Antev Limited, UK subsidiary.
- Dr. Mehmud will continue as Medicus' Chief Medical Officer and Antev's Co-Chairman.
- The appointment is effective August 30, 2026.
- He succeeds Amit Kohli, who served as interim CEO of Antev since August 29, 2025.
- Dr. Mehmud brings over 20 years of global biopharmaceutical leadership experience.
- The change aims to strengthen leadership for Teverelix® development and regulatory activities.
Price Impact
More from MDCX